Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website http://www.cardiologyres.org

Original Article

Volume 11, Number 5, October 2020, pages 305-310

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval

Figure

Figure 1.
Figure 1. Scatter plot of hs-troponin I to TpTe interval. Hs: high sensitive; TpTe: T peak to T end.

Tables

Table 1. Baseline Characteristics
 
CharacteristicsN = 25
BMI: body mass index; SD: standard deviation; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; LVEF: left ventricular ejection fraction.
Age (years), mean ± SD46 ± 7
BMI (kg/m2), mean ± SD24.9 ± 3.8
Anthracycline cumulative dose (mg/m2), mean ± SD591 ± 52
Comorbid, frequency, %
  Hypertension7 (28%)
  Diabetes mellitus4 (16%)
  Dyslipidemia2 (8%)
Medication, frequency %
  ACEI/ARB5 (20%)
  Calcium channel blocker2 (8%)
QTc interval (ms), mean ± SD462.5 ± 21.9
LVEF (%), mean ± SD67.4 ± 4.7

 

Table 2. Hs-Troponin I and TpTe Values
 
VariableBaselineAfter chemotherapyCorrelation coefficientP value
Hs-troponin I: high sensitive troponin I; TpTe: T peak to T end.
Hs-troponin I (ng/L)4.5 (1.5 - 15)90.5 ± 44.70.4210.018
TpTe interval (ms)73.9 ± 59.8108.2 ± 10

 

Table 3. Univariate Analysis of Confounding Factors
 
VariableT peak to T end
Correlation coefficientP value
BMI: body mass index.
Age (years)-0.1690.420
BMI (kg/m2)-0.1800.389
Cumulative anthracycline dose0.4070.044
Hypertension-0.1910.361
Diabetes mellitus-0.3670.071

 

Table 4. Multivariate Analysis
 
VariableUnstandardized coefficientsStandardized coefficientsP valueR2
BSEBeta
Hs-troponin I: high sensitive troponin I; SE: standard error.
Constants57.52820.1210.0090.318
Hs-troponin I0.0880.0400.3920.037
Cumulative anthracycline dose0.0720.0340.3770.044
Constants99.6424.274< 0.0010.177
Hs-troponin I0.0940.0420.4210.036